Faculty Bibliography

PURPOSE: There is considerable controversy over the treatment of medication-related osteonecrosis of the jaw (MRONJ) and growing interest and debate related to the timing, type, technique, and goals of surgical intervention. The specific aim was to evaluate the predictive value of fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography (CT) on healing outcomes in patients undergoing surgery for MRONJ of the mandible. MATERIALS AND METHODS: A retrospective cohort study of 31 patients with 33 MRONJ lesions of the mandible who had undergone surgery using FDG PET-CT was conducted. Data were collected on FDG uptake patterns, healing, follow-up, demographics, lesion characteristics, antiresorptive therapy, and adjunctive therapy. Panoramic and periapical radiographs were used to identify non-restorable teeth and PET-CT images were used to identify sequestra and FDG uptake. Above the mandibular canal, surgery consisted of marginal resection or debridement of clinically involved bone and exposure of clinically uninvolved bone identified by FDG uptake. Below the mandibular canal, mobile segments of bony sequestra were removed, but areas of clinically uninvolved bone with FDG uptake were not. Patients who did not heal underwent segmental resection and reconstruction with rigid fixation and a local or regional soft tissue flap or free fibular flap. The primary predictor variable was the FDG uptake pattern for each patient. The outcome variable was postoperative healing defined by mucosal closure without signs of infection or exposed bone at the time of evaluation. RESULTS: Two risk groups were identified based on FDG uptake pattern. The low-risk group, type A, included 22 patients with activity limited to the alveolus, torus, and basal bone superior to the mandibular canal. The high-risk group, type B, included 11 patients with type A FDG activity with extension inferior to the mandibular canal. Treatment of type A MRONJ lesions was more successful than treatment of type B MRONJ lesions (100 vs 27%; P < .001). Seven of the type B failures were successfully retreated by segmental resection and reconstruction (1 patient refused further treatment). CONCLUSION: These results showed that low-risk FDG PET-CT findings predicted successful healing with surgery above the mandibular canal. In contrast, high-risk FDG findings were associated with a greater than 50% risk of failure for treatment that extended below the mandibular canal. Although these failures suggest that FDG uptake indicates infected tissue, further research is needed to identify which high-risk patients are most likely to benefit from a conservative treatment protocol.

Quantitative standardized uptake values (SUVs) from fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) are commonly used to evaluate the extent of disease and response to treatment in breast cancer patients. Recently, PET/magnetic resonance imaging (MRI) has been shown to qualitatively detect metastases from various primary cancers with similar sensitivity to PET/CT. However, quantitative validation of PET/MRI requires assessing the reliability of SUVs from MR attenuation correction (MRAC) relative to CT attenuation correction (CTAC). The purpose of this retrospective study was to assess the utility of PET/MRI-derived SUVs in breast cancer patients by testing the hypothesis that SUVs derived from MRAC correlate well with those from CTAC. Between August 2012 and May 2013, 35 breast cancer patients (age 37-78 years, 1 man) underwent clinical 18F-FDG PET/CT followed by PET/MRI. One hundred seventy metastases were seen in 21 of 35 patients; metastases to bone in 16 patients, to liver in seven patients, and to nonaxillary lymph nodes in eight patients were sufficient for statistical analysis on an organ-specific per patient basis. SUVs in the most FDG-avid metastasis per organ per patient from PET/CT and PET/MRI were measured and compared using Pearson's correlations. Correlations between CTAC- and MRAC-derived SUVmax and SUVmean in 31 metastases to bone, liver, and nonaxillary lymph nodes were strong overall (rho = 0.80, 0.81). SUVmax and SUVmean correlations were also strong on an organ-specific basis in 16 bone metastases (rho = 0.76, 0.74), seven liver metastases (rho = 0.85, 0.83), and eight nonaxillary lymph node metastases (rho = 0.95, 0.91). These strong organ-specific correlations between SUVs from PET/CT and PET/MRI in breast cancer metastases support the use of SUVs from PET/MRI for quantitation of 18F-FDG activity.

Objectives PET/MR may be used in the evaluation of cognitively impaired patients. There are known quantitative differences between PET images obtained on PET/MR scanners when reconstructed with Dixon-MR, CT-based or atlas-based attenuation correction (AC) maps. This study seeks to assess the impact, if any, of these three-different AC methods on the blinded visual interpretation of regional hypometabolism in patients with cognitive impairment. Methods Forty-five minutes following injection of 10 mCi of FDG, 15 patients with cognitive impairment underwent brain PET/CT. PET/MR scanning with a 10 minute PET acquisition and Dixon MR imaging was subsequently performed on a Siemens Biograph mMR scanner under an IRB-approved protocol, at approximately two hours post-injection. A manufacturer-provided non-product offline reconstruction tool was used to reconstruct PET data obtained from PET/MR with AC based on the patient's own CT images, a Dixon-MR derived AC map and an atlas-based AC map that combined Dixon-MR with a segmentation of bony skull structures. Two nuclear medicine physicians blindly scored brain regions (frontal, temporal, parietal, occipital, precuneus) as normal versus hypometabolic using 2D and 3D images generated by MIM software. Abnormal regions were scored as mild, moderate, or severely hypometabolic (score of 0, 1, 2 or 3 respectively). The hypometabolism scores obtained using the different methods of AC were compared and reader agreement assessed. All statistical tests were conducted at the two-sided 5% significance level using SAS 9.3 (SAS Institute, Cary, NC). Results Regional hypometabolism versus normal metabolism was correctly classified (accuracy) for 150 regions in 15 patients by two readers on atlas- and Dixon-based AC map PET reconstructions (versus CT reference AC) for 94% (90 - 96% c.i.) and 93% (89 - 96% c.i.) of all regions. The averaged sensitivity/specificity for detection of any regional hypometabolism was 95%/94% and 90%/91% for atlas-based and Dixon-based AC maps, respectively, compared to the reference standard CT images. The mean absolute error of regional hypometabolism scores for atlas- and Dixon-based PET reconstructions (versus CT) was 0.25 +/- 0.44 and 0.21 +/- 0.42 . There were no statistically significant differences between the visual assessments. Intra-reader agreement for detection of regional hypometabolism was high, with similar outcome assessments when using atlas- and Dixon-corrected PET data in 93% and 93% of scored regions, respectively. The simple kappa coefficient to assess reader agreement in terms of hypometabolism versus normal regions was 0.82 for atlas- and 0.84 for Dixon-based AC. The weighted kappa coefficient to assess reader agreement in terms of the hypometabolism score was 0.75 for atlas- and 0.77 for Dixon-AC. Conclusions Despite the more accurate FDG SUV quantification with CT-based and atlas-based attenuation correction in brain PET/MR compared to Dixon AC, there were no measureable differences between the three AC methods with respect to visual identification of regional hypometabolism in the evaluation of cognitively impaired patients

To evaluate diagnostic accuracy of perfusion weighted imaging (PWI) and positron emission tomography (PET) using an integrated PET/MR system in tumor grading as well as in differentiating recurrent tumor from treatment-induced effects (TIE) in brain tumor patients. Twenty patients (Group A: treatment naive, 9 patients with 16 lesions; Group B: post-therapy, 11 patients with 18 lesions) underwent fluorine 18 (18F) fluorodeoxyglucose (FDG) brain PET/MR with PWI. Two blinded readers predicted low versus high-grade tumor (for Group A) and tumor recurrence versus TIE (for Group B) based solely on tumor rCBV (regional cerebral blood volume) and SUV (standardized uptake values). Tumor histopathology at resection was the reference standard. Using rCBVmean 0.403), Group B (p > 0.06) and in the entire population (p > 0.07). Best overall sensitivity and specificity were obtained using rCBVmean